Biotech Values

[zipjet]

ABBV’s share-price decline this week can be explained by the broad biotech sell-off as well as heightened fears that PBMs and other third-party payers will pressure Humira pricing in the next few years, perhaps by encouraging adoption of Humira FoBs.

Assigning causation is dicey.

But I think that there is a perception ABBV shot themselves in the foot by too aggressive a discount.